- Home
- CCEP vs BDX Comparison
CCEP vs BDX Comparison
Compare CCEP & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEP | BDX |
|---|---|---|
| Founded | 1986 | 1897 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3B | 43.0B |
| IPO Year | 2015 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CCEP | BDX |
|---|---|---|
| Price | $108.56 | $170.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $104.33 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 02-17-2026 | 05-07-2026 |
| Dividend Yield | 2.48% | ★ 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $4.86 | N/A |
| Revenue Next Year | $3.79 | $3.02 |
| P/E Ratio | ★ $20.93 | $674.88 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $84.66 | $140.11 |
| 52 Week High | $113.67 | $213.08 |
Technical Indicators
Market Signals| Indicator | CCEP | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 56.32 | 65.56 |
| Support Level | $89.82 | $163.44 |
| Resistance Level | $109.28 | $196.05 |
| Average True Range (ATR) | 2.34 | 3.81 |
| MACD | -0.29 | 1.07 |
| Stochastic Oscillator | 50.27 | 88.05 |
Price Performance
Historical ComparisonAbout CCEP Coca-Cola Europacific Partners plc
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.
About BDX Becton Dickinson and Company
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.